MedPath

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Registration Number
NCT04108195
Lead Sponsor
Janssen Research & Development, LLC
Brief Summary

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

Detailed Description

Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or teclistamab with or without pomalidomide may lead to enhanced clinical responses in treatment of relapsed or refractory multiple myeloma through multiple mechanisms of action. Daratumumab is human immunoglobulin G1 kappa monoclonal antibody (IgG1k) that binds with high affinity to a unique epitope on cluster of differentiation 38 (CD38) in a variety of hematological malignancies including multiple myeloma. Talquetamab and teclistamab are bispecific T cell redirection antibodies. Talquetamab binds to cluster of differentiation 3 (CD3) receptor complex on T cells and to G protein-coupled receptor family C group 5-member D (GPRC5D), a 7-transmembrane receptor protein on plasma cells and teclistamab binds to human and cynomolgus-CD3 and B cell maturation antigen (BCMA). Purpose of study is to evaluate safety of daratumumab in combination with talquetamab and teclistamab with or without pomalidomide, and to evaluate preliminary antitumor activity of each combination. Study consists of a screening period, treatment period (Part 1: dose escalation and Part 2: dose expansion), a Post-treatment Follow-up Period (after the last dose of study drug and will continue for up to 16 weeks for each subject), and a Long-term Extension Period. The study will end when one of the following occurs: 1) the study drug has received marketing authorization and, if regionally applicable, government reimbursement is available; 2) a long-term extension rollover study has commenced for participants who are still benefiting from study treatment as determined by their investigator; or 3) all participants have discontinued study treatment. Total duration of study is approximately 5 years and 6 months. Efficacy, safety, pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed at specified time points. Participants safety will be monitored throughout study by Study Evaluation Team (SET). SET consists of members of sponsor's study team and participating investigators.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
290
Inclusion Criteria
  • Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
  • Must have either of the following: a) received at least 3 prior lines of therapy including a proteasome inhibitor (PI) (greater than or equal to [>=] 2 cycles or 2 months of treatment) and an immunomodulatory drug (IMiD) (>=2 cycles or 2 months of treatment) in any order during the treatment or b) disease that is double refractory to a PI and an IMiD
  • Measurable disease at screening as defined by any of the following: Serum monoclonal protein (M-protein) level >=1.0 grams per deciliter (g/dL) (in non- immunoglobulin G (IgG) myeloma, an M-protein level >=0.5 g/dL); or Urine M-protein level >=200 milligrams (mg)/24 hours; or Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 at screening and at Cycle 1, Day 1 predose
  • Female participants of childbearing potential must have a negative highly-sensitive serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test (less than [<] 5 international units per milliliter [IU/mL]) at screening and a negative urine or serum pregnancy test within 1 day before the first dose of study drug
Exclusion Criteria
  • Treatment in the prior 3 months with an anti- cluster of differentiation 38 (CD38) therapy (example, daratumumab), or discontinuation of a prior anti-CD38 therapy at any time due to an adverse event related to the anti-CD38 therapy
  • Live, attenuated vaccine within 4 weeks prior to the first dose of study drug unless approved by sponsor
  • Active Central nervous system involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
  • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded
  • Active hepatitis C infection as measured by positive hepatitis C virus- ribonucleotide (HCV)-RNA testing. Participants with a history of Hepatitis C virus antibody positivity must undergo HCV-RNA testing

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part 2: Dose ExpansionPomalidomideParticipants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
Part 1: Dose EscalationPomalidomideParticipants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
Part 1: Dose EscalationTeclistamabParticipants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
Part 1: Dose EscalationDaratumumabParticipants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
Part 2: Dose ExpansionTalquetamabParticipants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
Part 1: Dose EscalationTalquetamabParticipants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
Part 2: Dose ExpansionDaratumumabParticipants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
Part 2: Dose ExpansionTeclistamabParticipants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
Primary Outcome Measures
NameTimeMethod
Part 1: Number of Participants With Dose Limiting Toxicity by SeverityUp to 52 Weeks

The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.

Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Up to 52 Weeks

The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.

Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Up to 48 Weeks

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product.

Part 2: Number of Participants With Adverse Events and SAEs by SeverityUp to 48 Weeks

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product.

Secondary Outcome Measures
NameTimeMethod
Serum Concentration of TeclistamabUp to 52 Weeks

Serum concentration of teclistamab will be assessed.

Number of Participants With Anti-Drug Antibodies to TeclistamabUp to 52 Weeks

Number of Participants with anti-drug antibodies to teclistamab will be assessed.

Biomarker Assessment of DaratumumabUp to Cycle 7 Day 1 (each cycle of 28-days)

Serum cytokine concentrations will be measured at the time of drug infusion of daratumumab for biomarker assessment.

Biomarker Assessment of TalquetamabUp to Cycle 7 Day 1 (each cycle of 28-days)

Serum cytokine concentrations will be measured at the time of drug infusion of talquetamab for biomarker assessment.

Biomarker Assessment of TeclistamabUp to Cycle 7 Day 1 (each cycle of 28-days)

Serum cytokine concentrations will be measured at the time of drug infusion of teclistamab for biomarker assessment.

Number of Participants With Anti-Drug Antibodies to TalquetamabUp to 52 Weeks

Number of participants with anti-drug antibodies to talquetamab will be assessed.

Overall Response Rate (ORR)Up to 48 Weeks

ORR is defined as the percentage of participants who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.

Clinical Benefit RateUp to 48 Weeks

Clinical benefit rate (ORR + minimal response \[MR\]) is defined as the of participants who have a MR or better according to the IMWG criteria.

Duration of Response (DOR)Up to 48 Weeks

DOR is defined as the time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.

Time to ResponseUp to 48 Weeks

Time to response is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.

Serum Concentration of DaratumumabUp to 52 Weeks

Serum concentration of daratumumab will be assessed.

Serum Concentration of TalquetamabUp to 52 Weeks

Serum concentration of talquetamab will be assessed.

Number of Participants With Anti-Drug Antibodies to DaratumumabUp to 52 Weeks

Number of participants with anti-drug antibodies to daratumumab will be assessed.

Trial Locations

Locations (24)

Arthur J E Child Comprehensive Cancer Centre

🇨🇦

Calgary, Alberta, Canada

City of Hope National Medical Center

🇺🇸

Duarte, California, United States

City of Hope Orange County Lennar Foundation Cancer Center

🇺🇸

Irvine, California, United States

University of California San Francisco

🇺🇸

San Francisco, California, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Vanderbilt Ingram Cancer Center

🇺🇸

Nashville, Tennessee, United States

Medical College Of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

The Blavatnik Family Chelsea Medical Center at Mount Sinai

🇺🇸

New York, New York, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Wake Forest Baptist Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

University Health Network UHN Princess Margaret Cancer Centre

🇨🇦

Toronto, Ontario, Canada

Universitatsklinikum Freiburg

🇩🇪

Freiburg, Germany

Universitaetsklinikum Hamburg Eppendorf

🇩🇪

Hamburg, Germany

Universitaetsklinikum Heidelberg

🇩🇪

Heidelberg, Germany

Universitatsklinikum Wurzburg

🇩🇪

Wuerzburg, Germany

VU Medisch Centrum

🇳🇱

Amsterdam, Netherlands

LUMC

🇳🇱

Leiden, Netherlands

Hosp Clinic de Barcelona

🇪🇸

Barcelona, Spain

Inst. Cat. Doncologia-H Duran I Reynals

🇪🇸

Barcelona, Spain

Germans Trias I Pujol

🇪🇸

Barcelona, Spain

Hosp Univ Fund Jimenez Diaz

🇪🇸

Madrid, Spain

Clinica Univ. de Navarra

🇪🇸

Pamplona, Spain

Hosp Clinico Univ de Salamanca

🇪🇸

Salamanca, Spain

© Copyright 2025. All Rights Reserved by MedPath